ReviewMolecular neurobiology2025
CircRNA-Based Therapeutics: a New Frontier in Neuroinflammation Treatment.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- circ_0044235 exacerbates neuroinflammation and apoptosis following spinal cord injury by targeting miR-338-5p.Journal of orthopaedic surgery and research · 2026Article
- EV-associated non-coding RNAs in paediatric asthma airway remodelling: current mechanistic evidence and therapeutic perspectives.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation is a complicated and multifactorial reaction in the central nervous system (CNS) that contributes to the pathophysiology of many neurological illnesses, such as neurodegenerative diseases and traumatic brain injury. Circular RNAs (circRNAs) have been identified to play important regulatory roles in neuroinflammatory diseases, making for novel therapeutic concerns. This review provides an overview of recent studies targeting the modulation of circRNA to aid in neuroinflammation, utilizing both silencing and overexpression strategies to facilitate possible neuron protection from neuroinflammatory insults. Studies using silencing approaches, such as siRNA or shRNA, have provided evidence that targeting specific circRNAs, like circHIPK2, circMETTL9, and circCDC14A, can be achieved by regulating various biomolecules, including STAT3, chemokines, and p38 MAPK. In contrast, using plasmid or mimic transfection to overexpress circRNAs, such as circ_DLGAP4, circRNA001372, circDYM, and circDlgap4, demonstrates some potential to also enhance anti-inflammatory effects by targeting NF-κB and HSP90. Studies examining the relationships between circ-Shank3/TLR4, circ-CDR1as/TRAF3, and circ_0008146/Cx3cr1 further demonstrate that these axes influence the modulation of neuroinflammation in response to various activators. The objective of this review is to offer a comprehensive overview of the findings on circRNAs to date while reviewing the various mechanisms by which circRNAs have been described to affect neuroinflammation and also consider the possible future therapeutic applicability for circRNAs in this setting.
Indexed as
Identifiers
40745517What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.